Zdrowie i gospodarka · 08/09/2004
National Cancer Institute Seeks Collaborators for Antiangiogenic Drug Development
The National Cancer Institute is seeking partners to develop novel antiangiogenic agents targeting adrenomedullin gene products for potential clinical testing and licensing opportunities.